Status:

UNKNOWN

Pilot Study of Partial Breast Irradiation Utilizing Permanent Breast Seed Implant to Treat Breast Cancer

Lead Sponsor:

British Columbia Cancer Agency

Collaborating Sponsors:

BC Cancer Foundation

Conditions:

Breast Cancer

Eligibility:

FEMALE

Up to 60 years

Phase:

NA

Brief Summary

Background: Recent single arm studies have suggested that partial breast irradiation (PBI), delivered in a relatively short overall treatment time of a few days, may be an effective alternative to adj...

Eligibility Criteria

Inclusion

  • Female subject with a pathologically-confirmed diagnosis of invasive ductal carcinoma.
  • Tumor size \< 2cm.
  • Negative axillary node involvement, determined by either
  • Sentinel node biopsy,
  • Axillary node dissection removing \> 6 nodes
  • No evidence of metastatic disease.
  • Treated by BCS with microscopically clear resection margins (\> 2mm to ink) for invasive and non-invasive disease or no residual disease on re-excision.

Exclusion

  • Age \< 60 years.
  • Subjects who will receive adjuvant chemotherapy.
  • A known deleterious mutation in BRCA-1 and/or BRCA-2.
  • Extensive DCIS, mammographically or pathologically.
  • Tumor histology of pure lobular carcinoma (invasive or in-situ).
  • Adenoid cystic and non-epithelial malignancies (e.g. sarcoma or lymphoma).
  • Lymphovascular invasion (LVI) present.
  • Bilateral invasive malignancy of the breast (synchronous or metachronous).
  • More than one ipsilateral breast primary tumor.
  • Previous irradiation to the ipsilateral breast.
  • Presence of an ipsilateral breast implant.
  • Serious non-malignant disease that precludes radiation treatment or conscious sedation.
  • Unable for any reason to undergo PBSI within 14 weeks of the last breast surgery.
  • Concomitant malignancies, except non-melanoma skin cancer and carcinoma in situ of any site.
  • Significant persistent post-surgical complications.
  • Currently pregnant or lactating.
  • Psychiatric or addictive disorders which would preclude obtaining informed consent.
  • Subject not committed to at least 3 years of follow-up.
  • Low CBC levels: HB \< 100 - Platelets \< 100 - Neutrophil count \< 1
  • Close partner not consenting
  • Inability to confidently localize/delineate the surgical cavity on CT and/or US.
  • Subject not suitable for a minimum 2-plane implant based on tumor location/breast size.
  • Seroma exceeding 3cm
  • Seroma within the inner quadrants

Key Trial Info

Start Date :

September 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 1 2016

Estimated Enrollment :

5 Patients enrolled

Trial Details

Trial ID

NCT01191164

Start Date

September 1 2011

End Date

September 1 2016

Last Update

August 25 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

British Columbia Cancer Agency

Victoria, British Columbia, Canada, V8R 6V5